Ultragenyx Pharmaceutical Inc.
RARE · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $673M | $560M | +20.2% |
| Operating income | −$535M | −$536M | +0.2% |
| Net income | −$575M | −$569M | −1.1% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 4, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $173M | $160M | +8.1% |
| Operating income | −$110M | −$171M | +35.7% |
| Net income | −$118M | −$180M | +34.4% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Ultragenyx Pharmaceutical's revenue in FY2025?
- $673M in FY2025 (Fiscal year ended Dec 31, 2025), +20.2% vs $560M a year earlier, per its 10-K filed Feb 2026.
- Was Ultragenyx Pharmaceutical profitable in FY2025?
- No: net income was −$575M and operating income −$535M in FY2025.
- What was Ultragenyx Pharmaceutical's revenue in Q3 2026?
- $173M (+8.1% vs a year earlier), per its Form 10-Q filed Nov 4, 2026.